Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
February 07, 2023 07:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that...
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
January 05, 2023 07:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) --...
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief...
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
December 19, 2022 16:05 ET
|
Myriad Genetics, Inc.
New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
December 08, 2022 19:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study...
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
November 29, 2022 16:05 ET
|
Myriad Genetics, Inc.
Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics,...
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
November 17, 2022 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
November 14, 2022 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and...
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
November 10, 2022 08:00 ET
|
Myriad Genetics, Inc.
UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) --...
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
November 03, 2022 18:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a...